<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
Exhibit 27
Financial Data Schedule
Mylan Laboratories Inc. and Subsidiaries
Article 5 of Regulation S-X
The schedule contains summary financial information extracted from the
Consolidated Balance Sheet at September 30, 2000, and the Consolidated Statement
of Earnings for the six months ended September 30, 2000, and is qualified in its
entirety by reference to such financial statements.
</LEGEND>
<CIK> 0000069499
<NAME> none
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> MAR-31-2001
<PERIOD-END> SEP-30-2000
<CASH> 219,339
<SECURITIES> 35,585
<RECEIVABLES> 262,411
<ALLOWANCES> 89,315
<INVENTORY> 198,391
<CURRENT-ASSETS> 685,468
<PP&E> 289,012
<DEPRECIATION> 114,056
<TOTAL-ASSETS> 1,334,213
<CURRENT-LIABILITIES> 228,914
<BONDS> 26,707
0
0
<COMMON> 65,261
<OTHER-SE> 997,251
<TOTAL-LIABILITY-AND-EQUITY> 1,334,213
<SALES> 374,810
<TOTAL-REVENUES> 374,810
<CGS> 203,525
<TOTAL-COSTS> 203,525
<OTHER-EXPENSES> 111,054
<LOSS-PROVISION> 586
<INTEREST-EXPENSE> 9
<INCOME-PRETAX> (66,531)
<INCOME-TAX> (23,951)
<INCOME-CONTINUING> (42,580)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (42,580)
<EPS-BASIC> (.34)
<EPS-DILUTED> (.33)
</TABLE>
